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INTRODUCTION
Rectal cancer (RC) constitutes 25% of all primary colorectal 
cancers, and is characterized by a different set of behavior pat-
terns, compared with tumors arising from the colon.1 In this 
regard, specific guidelines and protocols were conceived for 
the diagnosis, staging, and treatment of RC. Since the intro-
duction of sharp rectal dissection along the mesorectum by 
Heald,2 total mesorectal excision (TME) has become the cor-
nerstone of RC treatment, making a significant impact on lo-
cal recurrence and functional outcomes. A complete, margin-
negative resection is essential to confer the highest possibility 
of cure.3 Enhancements in imaging modalities have substan-
tially improved RC staging and patient stratification. The use 
of magnetic resonance imaging (MRI) has allowed for the 
high-resolution characterization of the extent of tumor involve-
ment, lymph node spread, and encroachment to neighboring 
organs. Moreover, extramural vascular invasion and a positive 
circumferential resection margin (CRM) on MRI have become 
important prognostic factors of recurrence and survival.4,5
In the last decade, there has been remarkable progress in 
RC treatment, characterized by relentless efforts to make sub-
stantial improvements in local control and the widespread 
adoption of a multidisciplinary approach. The use of neoadju-
vant chemoradiotherapy (CRT) has resulted in significant 
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Despite innovative advancements, the management of distally located rectal cancer (RC) remains a formidable endeavor. The 
critical location of the tumor predisposes it to a circumferential resection margin that tends to involve the sphincters and sur-
rounding organs, pelvic lymph node metastasis, and anastomotic complications. In this regard, colorectal surgeons should be 
aware of issues beyond the performance of total mesorectal excision (TME). For decades, abdominoperineal resection had been 
the standard of care for low-lying RC; however, its association with high rates of tumor recurrence, tumor perforation, and poorer 
survival has stimulated the development of novel surgical techniques and modifications, such as extralevator abdominoperineal 
excision. Similarly, difficult dissections and poor visualization, especially in obese patients with low-lying tumors, have led to the 
development of transanal TME or the “bottom-to-up” approach. Additionally, while neoadjuvant chemoradiotherapy has al-
lowed for the execution of more sphincter-saving procedures without oncologic compromise, functional outcomes remain an is-
sue. Nevertheless, neoadjuvant treatment can lead to significant tumor regression and complete pathological response, permit-
ting the utilization of organ-preserving strategies. At present, an East and West dualism pervades the management of lateral 
lymph node metastasis, thereby calling for a more global and united approach. Moreover, with the increasing importance of quality 
of life, a tailored, individualized treatment approach is of utmost importance when taking into account oncologic and anticipated 
functional outcomes.
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downstaging and downsizing of tumors, thereupon enabling 
the performance of sphincter-saving procedures in some cases.6,7
Despite the emergence of cutting-edge advancements, the 
management of low-lying RC remains challenging. Low RC is 
defined as a tumor located <6 cm from the anal verge, although 
other studies arbitrarily describe it as a tumor lying <5 cm from 
the anal verge.8,9 Although the surgical treatment of RC may 
be well standardized for tumors located in the high and middle 
rectum, the surgical treatment of low RC remains debatable. 
The higher risk of local recurrence in low RC, as well as the high-
er incidence of bowel dysfunction, has made its treatment a 
formidable endeavor.8 In addition, the critical location of a low 
RC tumor predisposes it to a CRM that tends to involve the 
sphincters and the surrounding organs, pelvic lymph node me-
tastasis, and anastomotic issues associated with radiation thera-
py.8 As a result, patients are susceptible to uncontrolled pelvic 
tumor, leading to sepsis, bleeding, fecal incontinence, sexual 
and urinary dysfunction, and pelvic pain.
In response to these challenges, alternative strategies have 
been explored and attempts to standardize the treatment of 
low-lying RC have been undertaken. In this review article, we 
critically examine recent advances in available techniques and 
contrasting philosophies, and highlight the critical and chal-
lenging issues confronted by colorectal surgeons in the man-
agement of low-lying RC in order to provide an avenue for a 
discussion about emerging progress in the field.




In previous years, abdominoperineal resection (APR) was 
deemed the standard surgical treatment for low-lying RC.10,11 
Advances in preoperative CRT and refinements in surgical 
skills led to a reduction in the number of patients undergoing 
the procedure; however, it is still indicated in patients with tu-
mor invasion to the external anal sphincter and levator muscles 
and in those with poor anorectal function and inadequate re-
sponse to CRT.6 A combination of anatomic and surgical chal-
lenges complicates conventional APR surgery. In the distal 
rectum, the mesorectal tissue tapers down at approximately 2 
cm above the levator ani muscles; thus, there is less protective 
tissue volume for the tumor to traverse before involving the 
CRM.12,13 Moreover, the conventional APR technique is associ-
ated with the technical difficulty of dissecting deep in the pel-
vis.14,15 Because of these inherent challenges, APR is associated 
with oncologic outcomes that are inferior to those of low ante-
rior resection, as well as with higher risks of intraoperative per-
forations and CRM involvement.6
Patient selection
The extralevator abdominoperineal excision (ELAPE) tech-
nique has been introduced to answer increasing calls for a mod-
ification of the conventional APR technique.10 Holm, et al.16 
from the Karolinska University Hospital in Stockholm devel-
oped a more radical procedure based on Miles’ original tech-
nique17 by applying an extended posterior perineal approach, 
which created a cylindrical specimen and avoided the “waist-
ing” associated with conventional APR. The technique was 
performed in patients in whom MRI showed a T3 or T4 tumor 
located within 6 cm from the anal verge or in those with fixed 
and tethered tumors on rectal examination.16 However, for tu-
mors with encroachment into the external sphincter or levator 
muscles and poor response to preoperative CRT, APR is still 
indicated.6
Surgical technique
The ELAPE technique closely resembles Miles’ original opera-
tion,17 which involves careful mobilization of the mesorectum 
up to the level of the levator muscles; however, in this approach, 
the abdominal and perineal dissections meet just above the 
levator muscles, leaving the levators attached to the mesorec-
tum and creating a cylindrical specimen with more tissue cov-
ering the tumor in the distal rectum. The perineal phase of the 
procedure is executed with the patient in the prone position. 
The extended perineal dissection follows the inferior surface 
of the levator muscles up until the level of the abdominal dis-
section termination. To enhance visualization, the coccyx is 
usually removed along with the main specimen. In cases where 
primary closure is not feasible, a gluteus maximus flap recon-
struction of the pelvic floor is performed to cover the perineal 
defect.15,16
Perioperative outcomes
In terms of perioperative outcomes, the initial results by Holm, 
et al.16 revealed that the extended perineal approach is associ-
ated with a lower risk of wound complications. In a study by 
West, et al.18 comparing ELAPE with traditional APR, ELAPE 
was associated with a longer operative duration (median oper-
ative time: 300 min vs. 185 min, p<0.001), as well as an increased 
incidence of coccyx removal (99 vs. 3, p<0.001), use of flap re-
construction (80 vs. 0, p<0.001), and perineal wound complica-
tions (from 20% to 38%, p=0.019). On the other hand, data from 
our institution revealed that ELAPE was better than conven-
tional APR in terms of operative time (median: 285 min vs. 355 
min, p=0.074), intraoperative bleeding volume (median: 300 
mL vs. 360 mL, p=0.546), and length of hospital stay (median: 10 
days vs. 17 days, p=0.016). There was no significant difference 
in terms of postoperative complications between the two.19
Oncological outcomes
Numerous studies have shown the oncologic superiority of the 
ELAPE technique, especially in terms of CRM involvement and 
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intraoperative perforations. A study by West, et al.18 demon-
strated the oncologic superiority of the ELAPE technique in a 
retrospective study by comparing specimens obtained from 
ELAPE to those taken using the conventional APR technique. 
Besides the clinical and pathologic parameters, tissue mor-
phometry was used to ascertain the volume of tissue removed 
around the tumor in both surgical techniques. The ELAPE tech-
nique cleared away more tissue at the distal rectum, which 
consequently resulted in lower rates of CRM involvement 
(14.8% vs. 40.6%, p=0.013) and intraoperative perforations 
(3.7% vs. 22.8%, p=0.0255), than conventional APR.15 Subse-
quently, West, et al.18 performed a multicenter study on ELA-
PE involving 11 colorectal surgeons based at nine European 
institutions. The results revealed that the ELAPE technique 
removed more tissue (median area: 2120 mm2 vs. 1256 mm2, 
p<0.001), causing a decrease in CRM involvement (from 49.6% 
to 20.3%, p<0.001) and intraoperative perforations (from 28.3% 
to 8.2%, p<0.001), than conventional APR. In a retrospective 
study from our institution, ELAPE achieved a longer lateral 
margin (median: 7.5 mm vs. 4.0 mm), harvested more lymph 
nodes (median: 17 vs. 12, p=0.076), and decreased the rate of 
harvesting <12 lymph nodes (23.1% vs. 46.2%, p=0.295), com-
pared with conventional APR (23.1% vs. 11.5%).19
Functional outcomes
Although studies have been limited, the functional outcomes 
of ELAPE have been encouraging. In the study by West, et al.,18 
there was no significant difference in terms of postoperative 
sexual and urinary dysfunctions between conventional APR 
and ELAPE. Likewise, in a prospective study by Vaughan-Shaw, 
et al.,20 quality of life (QoL) analysis after ELAPE showed high 
physical, emotional, and social functioning scores that were 
comparable to published data on functional outcomes of con-
ventional APR.
Summary
ELAPE is a feasible technique with acceptable perioperative, 
oncologic, and functional outcomes. Moreover, the aforemen-
tioned studies solidify the perception that it is comparable and 
not inferior to conventional APR. Clearly, the modified tech-
nique offered the advantages of reducing CRM involvement 
by removing the levator muscles along with the mesorectum 
and anal canal en bloc and increasing the amount of protec-
tive tissue around the tumor. In addition, the prone jackknife 
position provided better visualization by allowing the rectum 
to descend outward after opening the pelvis, thereby revealing 
the plane between the rectum and the adjacent organs and 
preventing inadvertent tumor perforation.18 The increased sus-
ceptibility to perineal wound complications has been consid-
ered the main drawback of the ELAPE procedure; however, this 
can be partially circumvented with the use of myocutaneous 
flaps. In this regard, more studies are needed to determine the 
factors that would assist in identifying patients with an in-
creased risk of perineal wound infections.
TRANSANAL TME: A NEW APPROACH  
TO TME
Introduction
Oncological outcomes, particularly local disease control, in 
RC depend heavily on obtaining a quality TME specimen with 
an intact mesorectum and adequate radial and distal margins. 
TME is a challenging procedure for even the best colorectal 
surgeons. In particular, visualization can be difficult in an obese 
patient with a bulky tumor and a narrow pelvis, leaving limit-
ed space for pelvic dissection. Having an anteriorly located dis-
tal tumor can also complicate the situation for these patients 
by predisposing them to a higher risk of CRM involvement.21 
Furthermore, difficult introduction of instruments and poor 
stapler ergonomics in the pelvis are obstacles in ensuring a se-
cure distal margin, requiring multiple stapler firings that can 
result in asymmetrical staple lines and increased risk of anas-
tomotic leakage.3 The use of a minimally invasive approach was 
introduced to provide better visualization and assist in rectal 
mobilization; however, the same anatomic challenges seen in 
open rectal surgery remain unanswered, especially the capa-
bility of securing an adequate distal margin and achieving a 
complete TME with an uninvolved CRM.3,22 Robotic surgery 
was introduced to compensate for the technical limitations of 
traditional laparoscopy. The robotic system provided improved 
dexterity and ergonomic efficiency through its stable camera, 
stereoscopic views, three-dimensional imaging, and seven de-
grees of articulation; nonetheless, it has failed to address the 
problems of securing an adequate distal margin and the diffi-
cult retraction deep in the pelvis.22-24 In response to these chal-
lenges, transanal TME (taTME), also referred to as “bottom-to-
up” TME, was developed to provide a more direct approach to 
the most complicated phases of dissection in the distal rectum, 
to assure an adequate distal resection margin, and to facilitate 
sphincter preservation.24
Patient selection
The performance of TME via a transanal approach evolved 
from previous experience with transanal local excision and ad-
vances in microsurgical endoscopic surgery.21 Indeed, it is an 
acquired concept combining important surgical techniques, 
such as transanal endoscopic microsurgery, transanal trans-
abdominal approach, and transanal minimally invasive sur-
gery.25 A consensus about the indications of taTME was pub-
lished after the Second International Transanal Total Mesorectal 
Excision Conference. Experts recommended taTME in pa-
tients with the following characteristics: 1) male sex, 2) nar-
row and deep pelvis, 3) obesity, 4) tumor >4 cm, 5) prostatic en-
largement, and 6) distorted planes caused by irradiation.26 
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Surgical technique 
Over the years, the taTME technique has gradually undergone 
refinements to allow for careful excision of low rectal tumors. 
At present, it is commonly executed as a combined procedure 
with both abdominal and perineal phases. These phases can be 
performed simultaneously, with separate surgical teams, or in 
sequence, beginning either transanally or transabdominally. 
The transanal phase is initiated by exposing the anal canal us-
ing a Lone Star retractor (Lone Star Medical Products, Hous-
ton, TX, USA). Initial rectal incision would vary depending on 
the location of the tumor in the anorectal canal. For tumors 
located distally or invading the anorectal junction (<1.5 cm), a 
partial intersphincteric dissection is carried out before the 
placement of a distal purse string at least 1 cm below the tu-
mor. For more proximal tumors, the rectal purse string is posi-
tioned at a safe distance that can secure a clear distal margin. 
The abdominal phase commences with trocar insertion and 
carbon dioxide insufflation at 15 mm Hg to facilitate the per-
formance of a full-thickness rectotomy. During this step, sur-
geons must be aware that an intramural dissection may occur 
and result in a positive margin. Subsequently, TME dissection 
is performed. After completion of the TME, the specimen is 
extracted either via the transanal or transabdominal route. 
Following specimen extraction, a hand-sewn or stapled colorec-
tal anastomosis or coloanal anastomosis (CAA) is performed.27,28 
Penna, et al.27 summarized taTME in five essential steps: 1) 
placement of a distal circumferential purse string, 2) full-
thickness rectotomy, 3) TME, 4) specimen extraction, and 5) 
anastomosis. 
Perioperative outcomes
Since the initial experience of Sylla, et al.29 and Lacy, et al.,30 
numerous studies have demonstrated encouraging results 
about the safety and efficacy of taTME. From 2011 to 2014, Lacy, 
et al.31 conducted a study in a prospective series of 140 taTME 
cases. The results showed no conversions or intraoperative 
complications. Pathological analysis revealed that a complete 
TME specimen was obtained in 97.1% of patients, whereas 
2.1% had a nearly complete mesorectum. Minor complications 
occurred in 24.2% of the patients, whereas 10% experienced 
major complications. No mortality was recorded in the series. 
Penna, et al.25 of the International taTME Registry Collabora-
tive published the results of the first 720 taTME cases from 66 
registries in 23 countries. taTME obtained intact TME speci-
mens in 85%. Abdominal conversion occurred in 6.3%, where-
as perineal conversion to a more extensive abdominal surgery 
was required in 2.8%. In short-term outcomes, the rates of post-
operative mortality and morbidity were 0.5% and 32.6%, re-
spectively.
Oncologic outcomes
In terms of oncologic outcomes, studies on taTME have dem-
onstrated encouraging results. In the series of de Lacy, et al.,31 
2.3% had local recurrence and 7.6% had systemic recurrence 
after a follow-up period of 15 months. Recently, Marks, et al.24 
published the first report on long-term outcomes of taTME for 
RC in a cohort of 373 patients. After a mean follow-up period 
of 5.5 years, the local recurrence and distant metastasis rates 
were 7.4% and 19.5%, respectively, and the 5-year survival rate 
was 90%. The long-term results of the study showed that taT-
ME is a promising technique that can yield adequate distal 
margins and CRMs with good-quality specimens.
Functional outcomes
The first prospective assessment of patients’ functional out-
comes and QoL after taTME has recently been published by 
Koedam, et al.32 Using validated questionnaires, patients who 
underwent taTME were evaluated at the VU University Medi-
cal Center in Amsterdam (Vrije Universiteit Amsterdam). One 
month after taTME, QoL, functioning, fatigue, functional bowel 
disturbance, generalized body pain, and anal scores were sig-
nificantly reduced; however, the scores reverted to baseline 
values after 6 months, except for anal pain and social function 
parameters.32 
Summary
Initial experience suggested that taTME has the potential of 
yielding better specimen quality, less morbidity owing to im-
proved anastomosis, and more sphincter-saving procedures 
without risking oncologic outcomes. Moreover, preliminary 
results on functional outcomes are comparable to those of lap-
aroscopic TME in published data, showing significant reduc-
tion in QoL parameters at 1 month after surgery, with subse-
quent recovery to baseline values by 6 months.33 The COLOR III 
trial, the first multicenter randomized clinical trial to compare 
taTME vs. laparoscopic TME, has begun. The trial was built on 
the premise that taTME would yield superior oncologic out-
comes to those of conventional laparoscopic TME, thereby 
reinforcing the results of previous cohort studies.34 Despite the 
encouraging initial results, surgeons must be judicious in adopt-
ing taTME into surgical practice. taTME is technically demand-
ing and requires steep learning curve. In addition, owing to 
the technical difficulties of distinguishing the correct tissue 
planes, surgeons should be aware of certain intraoperative com-
plications that may occur during taTME procedures, such as in-
juries to the urethra and major pelvic vessels.21,25 The wait for 
the results of the COLOR III trial is fueled with anticipation. In 
the meantime, structured taTME training and mentorship are 
essential for surgeons who wish to adopt the taTME technique, 
and more trials should be undertaken before its widespread 
implementation in surgical practice.26 
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SPHINCTER PRESERVATION
Intersphincteric resection and CAA: anal preservation 
in RC surgery
Introduction
Better understanding of sphincter anatomy, enhanced surgi-
cal techniques, and advances in CRT have brought about the 
evolution of RC treatment from APR to sphincter-preserving 
surgery (SPS).35 In recent years, ultralow anterior resection 
(uLAR) with or without intersphincteric resection (ISR) and 
CAA has been performed, enabling anal preservation with se-
cure distal and radial margins and striking a balance between 
oncologic cure and maintenance of anal function.36 In 1994, 
Schiessel, et al.36 introduced the groundbreaking technique 
involving the removal of the internal sphincter and dissection 
extending into the intersphincteric plane. To achieve an ade-
quate distal margin, a portion of the puborectalis or external 
sphincter may be removed with the specimen.36 With its ac-
ceptable oncologic outcome and preservation of anal function, 
adaptation of ISR with CAA has increased and has largely re-
placed APR; nevertheless, APR is still indicated when there is 
infiltration of the intersphincteric space to avoid leaving tumor 
cells at the resection margin.37 
Patient selection and types of ISR
Intersphincteric resection is indicated for patients with distal 
rectal tumors confined to the internal sphincter, not involving 
the external sphincter, and located below the anorectal ring 
within the surgical canal. In recent years, the technique has 
undergone significant refinements and modifications. Partial 
removal of the external sphincter is also performed if there is 
invasion into the intersphincteric space and/or external sphinc-
ter muscles.37,38 A Japanese study group defined three types of 
ISRs: Total ISR is performed when the tumor has spread be-
yond the dentate line, and involves complete removal of the 
internal sphincter. Subtotal ISR is performed when the distal 
edge of the tumor is >2 cm from the dentate line, and involves 
resection of two-thirds of the internal sphincter. Partial ISR is 
performed when there is enough distal margin above the den-
tate line, and involves only resection of one-third of the inter-
nal sphincter (Fig. 1).38-41
Surgical technique
Meticulous dissection of the anatomical plane between the 
internal and external sphincters forms the basis of the ISR tech-
nique, which frequently involves three essential phases: an 
abdominal phase, followed by a perianal phase, and conclud-
ed by a second abdominal phase. The initial abdominal phase 
commences with ligation of the inferior mesenteric artery at 
the root of its origin from the abdominal aorta, with clearance 
of the lymph nodes along its course and division of the inferi-
or mesenteric vein beneath the pancreas. After adequate mo-
bilization of the descending and sigmoid colon up to the level 
of the splenic flexure, TME is performed and dissection pro-
ceeds down to the anal canal through the intersphincteric plane. 
The perianal phase of the procedure follows the complete dis-
section of the rectum and mesorectum. A Lone Star retractor 
(Lone Star Medical Products) is applied to expose the mucosa 
and allow better access and visualization. In this phase, a 1−2-
cm distal resection margin is of utmost importance and must 
be ensured whenever possible. A circumferential incision is 
utilized commencing at the intersphincteric groove. Posterior 
dissection is initiated at the intersphincteric groove for total 
ISR, at the level of the dentate line for partial ISR, and in be-
tween the dentate line and intersphincteric groove for subto-
tal ISR. The intersphincteric plane is utilized for the anterior 
and lateral dissections, progressing until the intraperitoneal 
rectum is reached. The tumor-bearing rectum is eventually de-
livered either through the anus or abdominal wound, and re-
sected with an adequate proximal margin. A coloanal tension-
free anastomosis is then performed. The procedure concludes 
with a second abdominal procedure for the placement of closed 
suction drains and creation of a diverting ileostomy.42,43
Postoperative outcomes
Numerous studies have demonstrated favorable surgical, on-
cological, and functional outcomes for ISR.38,39,44 In 2005, Schies-
sel, et al.45 published the long-term follow-up data of 121 pa-
tients who underwent ISR. Their findings revealed that the 30-
day complication rate after the operation was 7.7% (n=9), 
whereas the mortality rate was 0.8% (n=1). Among the 9 pa-
tients who experienced early postoperative complications, 7 
patients (5.1%) developed anastomotic fistula, which healed 
spontaneously, whereas the other 3 patients required surgical 
intervention. In terms of late complications, anastomotic stric-
ture occurred in 11 patients (9.4%), necessitating perianal dil-
atation.45 These findings were supported by a systematic review 
by Akagi, et al.,38 which revealed an overall complication rate 
ranging from 7.5% to 38% and an operative mortality rate of 
<2%. Anastomotic leakage occurred in 4.3−48%, with the devel-
opment of subsequent stricture observed in 8.4−15.9%. Aside 
from anastomotic leakage, postoperative complications also 
included ileus, colonic ischemia, pelvic abscess, and develop-
ment of ano-vaginal fistula.38 In recent years, a robotic platform 
has been introduced to overcome the inherent challenges of 
laparoscopy.46 Baek, et al.35 compared outcomes in 84 patients 
who underwent uLAR with those in patients who underwent 
CAA with or without ISR using the robotic or laparoscopic ap-
proach. The results revealed that patients who underwent ro-
botic surgery had lower conversion rates (robot 2.1% vs. lapa-
roscopy 16.2%, p=0.011) and had shorter hospital stays than 
patients in the laparoscopic group (robot 9 days vs. laparoscopy 
11 days; p=0.011). Likewise, a subsequent study at our institu-
tion revealed that postoperative recovery was significantly fast-
er after minimally invasive surgery (robotic and laparoscopic) 
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than after open surgery. The period of hospitalization, time 
until first flatus, and time until the initiation of soft diet were 
significantly shorter after minimally invasive surgery (unpub-
lished).47 Recently, Kim, et al.48 evaluated robotic ISR by com-
paring ISR and APR using either robotic or open approaches. 
The results revealed that the use of robotic surgery was the 
most significant predictor of ISR achievement [odds ratio (OR) 
3.467, 95% confidence interval (CI) 2.095−5.738, p<0.001]. Post-
operatively, surgical complications were more common in the 
open ISR group (16% vs. 7.7%, p=0.01).
Oncologic outcomes
Mounting evidence suggests that ISR is an oncologically ac-
ceptable surgical alternative to APR for low RC. In the long-
term cohort of Schiessel, et al.,45 5.3% (n=6) patients developed 
local recurrence and 3.5% (n=4) died within a median follow-
up time of 94 months. The systematic review by Akagi, et al.38 
yielded satisfactory oncologic outcomes, with reported overall 
recurrence, distant metastasis, and local recurrence rates of 
13.3−19.4%, 2.5−19.0%, and 0−22.7%, respectively. Similarly, 
the survival rates were favorable with disease-free and overall 
5-year survival rates ranging from 69% to 86% and 79% to 97%, 
respectively. The use of robotic systems has considerably influ-
enced the oncological outcomes of the ISR technique in recent 
years. Studies comparing long-term feasibility between robot-
ic ISR and laparoscopic ISR have demonstrated that there are 
no significant differences in terms of local recurrence, overall 
survival, or disease-free survival between the two techniques. 
Moreover, investigators have lauded the ergonomic efficiency 
of the robotic platform, with its improved dexterity and visual-
ization.48,49
Functional outcomes
Despite the introduction of anal preservation with ISR, anal 
dysfunction remains a major concern. Low anterior resection 
syndrome (LARS), consisting of symptoms of stool frequency, 
fecal incontinence, or urgency, frequently occurs after sphinc-
ter-preserving operations.38 In the long-term study by Schies-
sel, et al.,45 ISR resulted in a reduction of anal resting pressure, 
remaining constant during the whole observation period. In 
contrast, maximum squeeze pressure, which was significantly 
diminished after ISR, was gradually restored during the fol-
low-up period. Clearly, the aspect of time is essential in evalu-
ating functional outcomes after ISR. Several factors have been 
found to be inimical to anal function, predisposing patients un-
dergoing ISR to strictures, stool frequency, and fecal inconti-
nence.6 Particularly, preoperative CRT has been highlighted as 
an adverse factor affecting anal continence after ISR. In a long-
term study by Saito, et al.,50 despite 70% of patients showing 
good continence (Wexner score ≤10) at >5 years post-ISR, 
neoadjuvant treatment and male sex were shown to result in 
poor postoperative functional outcomes. In their experience, a 
more effective CRT was strongly associated with anal dysfunc-
tion, thereby reflecting the extent of neural degradation that 
would ensue during treatment.
Summary
The introduction of the ISR technique has challenged the con-
ventional belief that adequate fecal continence necessitates 
the preservation of an intact internal sphincter. Moreover, it 
has offered a feasible alternative for patients who would oth-
erwise need an APR. In our opinion, adequate preoperative 
planning, proper patient selection, and a precise technique 
with minimal trauma should be ensured to achieve success with 
this procedure. The implementation of a robot-assisted ap-
proach for ISR has allowed for efficient dissection into the in-
tersphincteric plane with its enhanced mechanical dexterity 
and clear visualization of the deep pelvis. Thus, we recommend 
careful patient selection to achieve adequate distal clearance 
and better functional results. The use of preoperative radiother-
apy has been shown to have a negative impact on anal function, 
making ISR patients susceptible to anastomotic strictures, 
stool frequency, and urinary incontinence.6 In this regard, we 
propose that assessment of anal function be performed before 
planning this type of surgery, taking into account the patient’s 
age and level of activity.
A B C D
Fig. 1. Schematic of surgical options for low lying rectal cancer. Adapted from Noh, et al. Ann Surg Treat Res 2017:93:195-202.41 (A) Intersphincteric re-
section for a tumor invading only the internal sphincter. (B) Abdominoperineal resection for a tumor invading beyond the internal sphincter. (C) Hemil-
evator excision for a tumor invading the levator ani muscle without external sphincter invasion. (D) Extralevator abdominoperineal resection for a tu-
mor invading both the levator ani muscle and external sphincter muscle.
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The advances in CRT, improvements in surgical instrumenta-
tion, and excellent pathological outcomes have allowed low-
lying RC to be approached in a multidisciplinary manner. The 
choice of procedure is always a matter of debate, especially 
when the goals are sphincter preservation and oncologic safe-
ty. Despite the recent advances in surgical techniques, total 
levator ani muscle excision to achieve an adequate CRM has 
routinely been performed for tumors at the level of the ano-
rectal junction. Nevertheless, there is the possibility that en 
bloc resection of the tumor-bearing rectum can be performed 
without compromising anal function in tumors limited to an 
ipsilateral levator ani muscle with an intact external anal sphinc-
ter. Anatomic studies have conveyed the existence of an ana-
tomic separation between the puborectalis muscle and the 
external anal sphincters.51,52
Patient selection and methodology
Recently, our institution introduced the hemilevator excision 
(HLE) technique followed by ISR and CAA to provide greater 
sphincter preservation and obtain oncologic clearance for tu-
mors partially invading one side of the levator ani. This tech-
nique exploits the advantages of the robotic platform in the 
dissection at the levator ani muscles and the 1-sided excision of 
the levator ani and deep part of the external sphincter through 
the intersphincteric plane.53 A preliminary report about this 
novel technique has recently been published. Data on 13 pa-
tients who underwent HLE at our institution were collected. 
RC tumors located at the level of the anorectal ring and invad-
ing or abutting the ipsilateral levator ani were included in the 
study, whereas tumors invading beyond the levator ani mus-
cle with extension toward the external sphincter, recurrent tu-
mors, and anal cancer were excluded. Preoperative long-
course chemoradiation (LCRT), consisting of 50.4 Gy in 28 
fractions for 6 weeks with two cycles of 5-fluorouracil or 
capecitabine-based chemotherapy, was administered to all 
patients, after which surgery was performed 4–8 weeks later. 
All of the 13 patients included in the study presented with low 
rectal tumors at the anorectal ring level that were suspected to 
encroach or border on the ipsilateral levator ani or pelvic floor 
muscles on MRI, even after preoperative LCRT.41
Surgical technique
HLE was carried out with the patient placed in a steep Lloyd-
Davies position. The procedure consisted of an abdominal 
and a perineal phase. The abdominal phase commenced with 
mobilization of the colon until the splenic flexure and ligation 
of the central vessels. Thereafter, TME was performed fol-
lowed by dissection toward the levator ani muscles. Then, 
rectal tumor and ipsilateral levator ani extirpation was per-
formed with an adequate margin. After pelvic floor dissection 
and HLE were achieved, the perineal phase of the procedure 
was initiated. During the perineal phase, the patient’s hips 
were placed in a flexed position to provide better access and 
visualization. The perineal phase commenced with an inci-
sion at the line of Hilton on the rectal tumor side to approach 
the intersphincteric space. Dissection was then advanced in 
between the internal and external anal sphincters 0.5−1 cm 
below the rectal tumor, where the course of dissection took a 
diagonal turn to include the deep portion of the external sphinc-
ter. The dissection was continued in the cephalad direction to 
encompass the levator ani muscle, before the pelvic cavity 
was entered. On the opposite side of the tumor, incision was 
made on top of the dentate line and dissection progressed to 
the medial plane of the internal sphincter, allowing entrance 
to the pelvic cavity. After complete removal of the rectum, the 
rectum and sigmoid colon were drawn out through the anus 
and transected. A sleeve-fashioned resection was performed 
to the distal rectum; thereafter, bowel continuity was restored 
using a hand-sewn CAA. A loop ileostomy was created in all 
patients who underwent the procedure.41 
Postoperative, oncologic, and functional outcomes
The HLE technique demonstrated favorable postoperative 
surgical outcomes. Anastomotic leakage necessitating percu-
taneous drainage manifested in 2 patients. Parastomal hernia 
occurred in 1 patient, requiring stomal revision. Oncological-
ly, a clear resection margin from the tumor was achieved in all 
cases. During follow-up, 1 patient had local recurrence at the 
anastomotic site 4 months after surgery, whereas 2 patients 
had systemic recurrences in the lung and liver at 25 and 6 months 
after surgery, respectively. In terms of functional outcomes, 
incontinence was evaluated using the incontinence grading 
scale recommended by Jorge and Wexner. Among the 6 pa-
tients who underwent takedown of ileostomy after the initial 
operation, 2 patients experienced fecal incontinence. One pa-
tient experienced two to three episodes of bowel movement 
per day that required a pad. The other incontinent patient ex-
perienced frequent episodes of bowel movement of >10 per day, 
but did not require the use of a pad. Among the patients who un-
derwent ileostomy reversal, the mean Wexner score was 9.4.41
Summary
The preliminary results of the HLE technique exemplify that 
the advent of cutting-edge imaging modalities has made pre-
operative evaluation more accurate, enabling a meticulous 
selection of patients for a specific surgical procedure. Particu-
larly, MRI has been helpful in delineating the exact location of 
a tumor, allowing patients otherwise considered to be APR can-
didates to undergo less extensive surgery.41 In contrast to the 
high rates of positive CRM after APR and extralevator APR in 
the literature, all patients in our series presented with negative 
CRM involvement. In addition, no patient presented with a 
positive distal resection margin, further reinforcing the onco-
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logic feasibility of the HLE technique. Moreover, the use of ro-
botic systems has permitted more precise dissections in the 
pelvic cavity, which has allowed HLE to be performed with 
adequate margins. On the basis of these preliminary results, 
we concluded that HLE might be a sensible alternative to APR 
or extralevator APR for low RC with invasion to the ipsilateral 
side of the levator ani muscle (Fig. 2). Notwithstanding the 
promising results, long-term outcomes, especially the effects 
on anorectal function, should be investigated, and a larger tri-
al needs to be undertaken before the technique can be widely 
implemented. 
PELVIC LYMPH NODE METASTASIS:  
A PHILOSOPHICAL DIVIDE
Introduction
Local recurrence remains a major problem in RC surgery, and 
is associated with severe morbidity and low survival. Regional 
lymph node spread and CRM involvement are independent 
prognostic factors of local recurrence. The presence of extra-
regional lymph node metastasis, which refers to lateral pelvic 
lymph nodes (LPLNs) or para-aortic lymph nodes, however, 
confers a higher recurrence rate.54 The high incidence of pel-
vic node metastasis remains a critical issue in the manage-
ment of low-lying RC, signifying that the disease has already 
escaped the confines of the regional space.55
Patient selection
The optimal management of LPLNs remains disputed, and 
has engendered a philosophical tug-of-war between the East 
and the West. The Japanese Society for Cancer of the Colon 
and Rectum guidelines for the treatment of cancer 2016 rec-
ommend TME/tumor-specific mesorectal excision and LPLN 
dissection (LPLND) to improve local control and survival in 
patients with advanced lower RC.56 They reported that, among 
patients whose lower tumor borders were located distal to the 
peritoneal reflection, the incidence of lateral lymph node me-
tastasis was 20.1%. These findings imply that TME alone can-
not eliminate potentially metastatic lymph nodes. Hence, LPLND 
is indicated if the tumor is located below the peritoneal reflec-
tion and invades further off the muscularis propria.56
Surgical technique
LPLND is a technically demanding technique, commencing 
after the completion of TME dissection. The ureter and hypo-
gastric nerve are secured to establish the inner border of dis-
section. After determining the iliac artery bifurcation as the 
cranial boundary of dissection, dissection proceeds along the 
external iliac artery and the external iliac vein until the major 
psoas muscle is reached. Once the presence of the obturator 
nerve, obturator vein, and obturator artery is confirmed, dissec-
tion proceeds in a caudal direction, with the dissection along 
the obturator artery progressing from its origin toward the pe-
riphery to allow complete extirpation of the obturator lymph 
node. After the removal of the obturator lymph node, dissec-
tion of the internal iliac lymph node begins and is carried out 
until the Alcock canal area to ensure completeness. A nerve-
sparing approach is adopted in removing suspicious malig-
nant lesions or malignant lateral lymph nodes. The extended 
lymphadenectomy is concluded with the en bloc removal of 
the tumor and lymph node specimen.57,58 
Postoperative outcomes
In contrast to Eastern countries, the gold standard in the West 
for treating pelvic lymph node metastasis involves preopera-
tive CRT followed by TME. LPLND has not been recommend-
ed in Europe or North America because of increased compli-
cations without improvement in overall survival.54 Lack of 
evidence and paucity of data have contributed to the contro-
versies about LPLN metastasis. In 2012, the JCOG0212 multi-
center, randomized controlled non-inferiority trial was under-
taken at 33 major hospitals in Japan. The trial aimed to compare 
postoperative morbidity and mortality after TME alone with 
TME with LPLND for stage II–III lower RC. Initial results re-
vealed that TME with LPLND resulted in longer operating 
times (360 min vs. 254 min, p<0.0001) and greater blood loss 
(576 mL vs. 337 mL, p<0.0001) than TME alone. There was no 
A B C D
Fig. 2. Schematic of hemilevator excision (HLE) and specimen. (A and B) Adapted from Noh, et al. Ann Surg Treat Res 2017:93:195-202.41 (A) Axial view 
of the extent of resection for HLE including the rectum and the invaded levator ani muscle. (B) Coronal view of the extent of resection for HLE through 
the intersphincteric plane and the sleeve-fashioned distal rectum resection. (C) Before the specimen was divided: right levator ani muscle (blue ar-
row) and right internal sphincter (orange arrow). (D) After the specimen was divided: right levator ani muscle (blue arrow), right internal sphincter (or-
ange arrow), and tumor (yellow circle). 
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significant difference in terms of grade 3 and 4 postoperative 
complications between the two groups (22% vs. 16%, respec-
tively).59
Oncological outcomes
An update of the JCOG0212 trial has recently been published. 
There was no difference in terms of relapse-free survival (73.4% 
vs. 73.3%, p=0.0547), overall survival (92.6% vs. 90.2%), or lo-
cal recurrence-free survival (87.7% vs. 82.3%) between the two 
groups. Nonetheless, the trial failed to confirm the non-inferi-
ority of TME alone to TME with LPLND in the intention-to-treat 
analysis, with TME with LPLND showing lower rates of local re-
currence than TME alone (7.4% vs. 12.6%, p=0.024).60 
Functional outcomes
The JCOG0212 trial demonstrated that the oncological out-
comes could be promising even in the absence of neoadjuvant 
CRT, which is the standard of care in Western countries. More-
over, the trial debunked previous concerns of an increased 
risk of urinary and sexual dysfunction after LPLND. According 
to the report on functional outcomes, the difference between 
the incidence of sexual dysfunction between patients who un-
derwent LPLND and those who did not was not statistically 
significant (68% vs. 79%, p=0.37). On further analysis, age was 
found to be the sole risk factor independently associated with 
sexual dysfunction after the operation (p=0.02).61 Moreover, 
LPLND did not significantly affect urinary capability, with an 
intraoperative blood loss of >500 mL solely predictive of uri-
nary dysfunction (relative risk 1.25, p=0.04).62
Summary
At present, variations in treatment algorithms exist, highlight-
ing the dualism that pervades lateral lymph node management 
in RC. Ending the ongoing debates would necessitate random-
ized controlled multicenter studies; however, the lack of ex-
pertise in LPLND outside of Japan and the inherent treatment 
biases across the East and West continue to be persistent bar-
riers.63,64 After an extensive review of the literature, we conclud-
ed that the ideal approach would be to reconcile the compet-
ing tenets of the East and the West, effectively combining 
neoadjuvant CRT and LPLND. After all, LPLND seems to be 
beneficial in patients with a lateral pelvic node diameter >10 
mm, representing a subgroup at high risk of lateral lymph 
node recurrence even after neoadjuvant CRT.65 MRI has been 
useful in determining lateral node metastasis, using a cutoff 
size of 6.0 mm in patients without CRT and 5.0 mm in patients 
with neoadjuvant treatment.66 As strides continue to be made 
in low RC treatment, there remains a pressing need for a more 
inclusive and cooperative approach to the lateral lymph node 
compartment, taking into account the merits of LPLND to im-
prove future oncological results and resolve the remaining 
controversies.
NON-OPERATIVE MANAGEMENT IN  
DISTAL RC: EXPLORING A NEW  
TREATMENT PARADIGM
Introduction
The concept of non-operative management (NOM) or a “watch 
and wait” strategy in low RC has gained popularity in recent 
years, representing a departure from the conventional treat-
ment paradigm that has long considered TME surgery its cor-
nerstone. Notwithstanding the type of approach, radical surgery 
has been associated with functional consequences, significant 
morbidity, and need for stomas. Moreover, the avoidance of 
surgery has been shown to improve survival in older adults 
with RC and in those with comorbidities.21,67
Patient selection
The observation that neoadjuvant CRT could induce significant 
tumor regression, with subsequent downstaging and downsiz-
ing of tumors, stimulated an interest in organ preservation 
strategies. Studies have documented that 15−30% of patients 
treated with neoadjuvant CRT develop complete pathologic 
response (pCR).68 Moreover, complete response of the tumor, 
termed complete clinical response (cCR), could be clinically 
evaluated in a subset of these patients. According to the propo-
nents of the NOM approach, patients who exhibit cCR would 
be the ideal candidates for organ preservation and the most 
likely to benefit from it.69
Evaluation of tumor response
Since its introduction by Habr-Gama, et al.70 in 2004, different 
cohort studies have shown that a NOM approach can be em-
ployed in carefully selected patients without oncologic com-
promise; nonetheless, the lack of standardized parameters in 
identifying cCR after CRT continue to be persistent issues.70-72 
Evaluation of the tumor response is of paramount importance 
in considering patients for NOM. Clinical assessment using 
digital rectal examination (DRE) and endoscopy serve as es-
sential tools in evaluating response. On DRE, cCR has been 
characterized by a smooth rectal wall and absence of irregu-
larities, mass, or ulceration. On the other hand, on endoscopy, 
cCR has been defined as whitening of the mucosa, telangiec-
tasia, and the absence of any residual mass, ulceration, or ste-
nosis.71 Likewise, radiological evaluation has become essen-
tial in confirming cCR within the rectal wall and providing 
information not accessible with finger examination and en-
doscopy, such as disease dissemination to the mesorectum 
and regional nodes.21 
Oncologic outcomes
The initial oncological results of patients who underwent 
NOM after achieving cCR following neoadjuvant CRT were 
reported to be equivalent to those of patients with pCR after 
surgery.70 Likewise, a recent meta-analysis comparing pa-
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tients managed non-operatively after cCR versus patients with 
pCR after TME found no statistical difference between the two 
groups in terms of non-regrowth recurrence, disease-free sur-
vival, overall survival, and cancer-specific mortality.73 Indeed, 
these studies lend further credence to the notion that patients 
who achieve cCR after neoadjuvant treatment can be spared 
from the consequences of radical surgery without oncologic 
compromise.
Functional outcomes and QoL
The main argument in favor of a NOM approach has been its 
promise of improved functional results and QoL compared with 
TME, without compromising good oncological outcomes; 
however, studies about QoL in NOM have been limited. A case-
matched controlled study by Hupkens, et al.74 comparing QoL 
between patients managed non-operatively and patients who 
underwent standard resection for RC has recently been pub-
lished. Their results revealed that patients with NOM had bet-
ter physical and emotional well-being, improved cognitive and 
physical function, and superior global health status than those 
who underwent TME. Moreover, patients with NOM exhibited 
fewer defecation, sexual, and urinary problems.74 
Summary
At present, most of the evidence on the efficacy of NOM derives 
from non-comparative single-arm studies. A recent propensi-
ty-score-matched cohort analysis has demonstrated that a 
sizable proportion of patients managed non-operatively have 
avoided surgery and permanent colostomy without compro-
mising oncological outcomes.75 In an age driven by evidence-
based recommendations, randomized controlled data dem-
onstrating oncological equivalence of NOM to radical surgery 
after the attainment of cCR following neoadjuvant CRT is still 
unavailable, necessitating future trials before NOM can be in-
corporated into practice as an alternative to radical surgery.
FUNCTIONAL OUTCOMES 
Bowel dysfunction
Most of the patients who undergo SPS for low-lying RC devel-
op LARS postoperatively. LARS after SPS can severely affect a 
patient’s QoL. Up to 90% of patients who undergo rectal resec-
tion can have altered bowel function after SPS.76 The symp-
toms are diverse, including increased frequency of bowel 
movement, urgency, fecal incontinence, sense of incomplete 
emptying, and fragmentation. Anal sphincter damage during 
the operation, reduced neorectal compliance as a reservoir, 
altered motility of the neorectum possibly caused by denerva-
tion during deep pelvic dissection, and preoperative CRT are 
presumed to be the main causes of postoperative bowel dys-
function after SPS.77 Many investigators have used self-made 
questionnaires that have not been validated or assessment 
tools focused on specific symptoms, such as fecal incontinence. 
Among the validated assessment tools, the Memorial Sloan 
Kettering Cancer Center bowel function instrument (MSKCC 
BFI) and LARS score are the most widely used. The MSKCC BFI 
is a detailed tool and deals with a wide symptomatic spectrum 
of LARS; however, it is time consuming to use. On the other 
hand, the LARS score is a good and practical tool for the quick 
screening of bowel dysfunction.
In surgery for low-lying RC, patients are at a risk of parasym-
pathetic nerve injury around the inferior mesenteric artery, 
and pelvic denervation from full mobilization of the rectum is 
inevitable owing to the low tumor level. Furthermore, the 
number of patients who receive neoadjuvant CRT has largely 
increased.
As multiple factors affect postoperative bowel dysfunction, 
all patients who are candidates for SPS should be counseled 
about the possibility of LARS, which might be severely detri-
mental to QoL, before surgery. They should be given the chance 
to weigh the burden of LARS against that of a permanent stoma.
Mahalingam, et al.78 reported the long-term functional out-
come of 33 patients who underwent ISR. After a median of 45 
months from restoration of bowel continuity, a mean number 
of bowel movements of <3 per 24 h was seen in 40% and 3–7 
per 24 h in 50%. On the first 1 year after ISR, the patients showed 
major LARS and high Wexner score; however, bowel dysfunc-
tion usually improved after 1 year. They found that most pa-
tients had a satisfactory QoL after ISR, and good bowel func-
tion was correlated with good QoL.78
In a systematic review of outcomes after ISR by Martin, et al.,79 
11−63% of patients complained of fecal soiling and 30−86% 
showed perfect continence. Although the assessment tools are 
inconsistent, the rates seem to vary across different studies.79 
Reports on the functional outcome after taTME confined to 
patients with low RC are limited. Most studies included RC at 
all levels. Koedam, et al.32 reported postoperative bowel func-
tion after taTME in patients whose median tumor height was 
6.0 cm from the anal verge [interquartile range (IQR) 4.0−8.0]. 
They found that the mean preoperative LARS score was 15.4 
(95% CI 7.3−23.5). The score increased to 35.7 at 1 month, and 
then decreased to 21.7 at 6 months.32
The TaLaR trial and ETAP-GRECCAR 11 trial are multicenter 
randomized controlled trials aiming to compare the short- 
and long-term outcomes between TaTME and laparoscopic 
TME for low RC.80,81 In these trials, the functional outcomes 
will be included among the secondary endpoints.80,81 
HLE has a concern of inevitable postoperative bowel dys-
function owing to unilateral excision of the levator muscle. In 
the preliminary report on 13 patients with low RC who under-
went HLE with a postoperative follow-up duration of 11.0 
months (IQR 8.5−27.0), the mean Wexner score after stoma 
closure was 9.4±5.7.41
The functional outcomes of NOM have not been fully inves-
tigated; however, the assumed benefit of NOM delays the mor-
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bidity and mortality and associated functional detriment of 
surgery. Maas, et al.82 reported the functional outcomes in their 
pilot study, in which the MSKCC and Wexner scores were as-
sessed for 21 patients with NOM. Compared with patients 
who underwent surgery and showed pCR, patients with NOM 
showed higher MSKCC scores (better bowel function) and low-
er Wexner scores (lower fecal incontinence).82 Appelt, et al.83 
reported that 72% of patients had no fecal incontinence at 1 year, 
and 69% at 2 years, among a total of 50 patients with NOM 
(total radiation dose of 66 Gy with concomitant chemothera-
py of oral tegafur-uracil). Hupkens, et al.74 recently reported 
that patients with NOM showed better bowel function than 
did patients treated with CRT followed by TME, demonstrat-
ing lower rates of major LARS (one third in the NOM group vs. 
66.7% in the CRT followed by TME group).
Urinary and sexual dysfunction
In terms of sexual and voiding functions, a number of studies 
have demonstrated the importance of pelvic autonomic nerve 
preservation and the effect of preoperative radiotherapy. A 
Dutch TME trial showed overall sexual dysfunction in 76% of 
male patients and 62% of female patients.84 Voiding dysfunc-
tions, including urinary incontinence, retention, urgency, and 
incomplete voiding, are known to be less severe than sexual 
dysfunctions, and the incidence has been reported to be >30%.84 
The most widely used validated assessment tools for urinary 
function are the International Prostate Symptom Score and 
Bristol female lower urinary tract symptom, and those for sex-
ual function are the International Index of Erectile Function 
and Female Sexual Function Indices. 
The most important point in preventing urinary and sexual 
dysfunction is to avoid injury to the autonomic nerves, includ-
ing the superior and inferior hypogastric nerve plexus and neu-
rovascular bundles going into genitourinary organs. Failure in 
bladder emptying is generally known to resolve within 3 
months; however, symptoms persisting after 6 months are re-
ported to be mostly permanent.85 Sexual dysfunction from par-
tial injury of nerves is known to usually resolve within 3–6 months; 
however, delay in the treatment of sexual dysfunction might 
lead to permanent dysfunction.86 
Solomon, et al.87 reported that there were significant discor-
dance in decision-making, and their study showed that many 
patients with RC were willing to trade survival for QoL. With 
more diverse treatment options becoming available, not only 
oncologic outcomes but also functional outcomes should be 
taken into account when deciding treatment strategies. There-
fore, patients should be informed about the functional aspects 
and be involved in the decision-making process.
CONCLUSION
As the incidence of colorectal cancer increases, colorectal sur-
geons should be cognizant of the issues extending beyond the 
performance of TME. APR and ISR are acceptable surgical 
procedures for treating low-lying RC; however, improvement 
of surgical skills is of paramount importance as novel tech-
niques are being introduced. At present, a more cohesive ap-
proach that effectively combines LPLND and neoadjuvant 
CRT is needed to overturn the East and West dichotomy in the 
treatment of lateral lymph node metastasis. The evidence rel-
ative to NOM has demonstrated that the consequences of sur-
gical treatment can be avoided, thereby challenging a treat-
ment paradigm that has long considered surgery its cornerstone. 
With the increasing treatment options for low RC, QoL has 
become a major issue; thus, tailored treatment that takes into 
account both oncologic and anticipated functional outcomes 
is essential. In this regard, patient participation in the deci-
sion-making process is crucial, as this makes them aware of the 
potential impact of the treatment on their bowel, urinary, and 
sexual function.
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